GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. The British Big Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results